The study aims to demonstrate that, in patients with heart failure treated at the best of recommended therapies, long term administration of (a) n-3 PUFA, (b) rosuvastatin is more effective than the corresponding placebo in the reduction of:

		All-cause mortality
		All-cause mortality or hospitalizations for cardiovascular reasons